Results From Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm Corporation (ARDM)’s Liposomal Ciprofloxacin To Be Presented At The American Thoracic Society 2014 International Conference
4/15/2014 6:51:07 AM
Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the “Company”) demonstrated that after 4 days of in vitro treatment of macrophages infected with Mycobacterium avium and Mycobacterium abscessus, Aradigm’s liposomal ciprofloxacin was associated with a decrease of greater than 99% of these infections at ciprofloxacin concentrations of 200 mcg/ml, which approximate the peak sputum levels observed in humans in prior Aradigm clinical studies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by